Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2004 Jun;12(2):91–97. doi: 10.1080/10647440400003873

Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analyses of a unique database.

Per-Anders Mårdh 1, Jolanta Wågström 1, Maria Landgren 1, Jan Holmén 1
PMCID: PMC1784597  PMID: 15739823

Abstract

OBJECTIVES: To present sales figures of antifungal drugs for treatment of genital Candida infections in females, which had been purchased in the Swedish county of Skåne (with approximately 1.2 million inhabitants) during the 1990s. To study the relative proportions of the drugs sold by prescription and as over-the-counter (OTC) products. METHODS: Sales figures of antifungal drugs for therapy of vulvovaginal candidiasis (VVC) and such recurrent infections (RVVC), for the years 1990--99, were collected from the 'ACS' database of the National Corporation of Swedish Pharmacies. RESULTS: The study showed an increase in sales of the type of drugs studied from 45,000 packages in 1990 until mid-93/94, when approximately 70,000 packages were sold (mainly azoles for topical use and fluconazole for oral intake). Thereafter there was a decrease until the end of November 1999, when 54,000 packages were purchased. Of the total sales, 93% were OTC products. Sales of clotrimazole and econazole (for vaginal installation) in 1993--1994 were equal to 85-90 packages/1000 women in the age group 15-45 years. Extremely high sales volumes of fluconazole and itraconazole, for one single year each, could be explained by marketing-related activities directed to the medical community. CONCLUSIONS: As many women with RVVC are not cured by iatrogenic initiatives and women consider themselves able to diagnose episodes of genital Candida infection, affected women generally turn to self-medication with antifungal OTC products. This stresses the role of pharmacy counseling. Short-term marked alterations in sales volumes may be due to marketing factors rather than changes in the epidemiology of genital Candida infections.

Full Text

The Full Text of this article is available as a PDF (93.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ferris D. G., Dekle C., Litaker M. S. Women's use of over-the-counter antifungal medications for gynecologic symptoms. J Fam Pract. 1996 Jun;42(6):595–600. [PubMed] [Google Scholar]
  2. Frega A., Gallo G., Di Renzi F., Stolfi G., Stentella P. Persistent vulvovaginal candidiasis: systemic treatment with oral fluconazole. Clin Exp Obstet Gynecol. 1994;21(4):259–262. [PubMed] [Google Scholar]
  3. Lynch M. E., Sobel J. D., Fidel P. L., Jr Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol. 1996 Sep-Oct;34(5):337–339. doi: 10.1080/02681219680000571. [DOI] [PubMed] [Google Scholar]
  4. Mårdh Per-Anders, Rodrigues Acacio G., Genç Mehmet, Novikova Natalia, Martinez-de-Oliveira J., Guaschino Secondo. Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS. 2002 Aug;13(8):522–539. doi: 10.1258/095646202760159639. [DOI] [PubMed] [Google Scholar]
  5. Novikova Natalia, Mårdh Per-Anders. Characterization of women with a history of recurrent vulvovaginal candidosis. Acta Obstet Gynecol Scand. 2002 Nov;81(11):1047–1052. [PubMed] [Google Scholar]
  6. Nwokolo N. C., Boag F. C. Chronic vaginal candidiasis. Management in the postmenopausal patient. Drugs Aging. 2000 May;16(5):335–339. doi: 10.2165/00002512-200016050-00003. [DOI] [PubMed] [Google Scholar]
  7. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  8. Rodrigues A., Vaz C. P., Mårdh P. A., da Fonseca A. F., de Oliveira J. M. In vitro effect of fibrinogen on Candida albicans germ tube formation. APMIS. 1999 Nov;107(11):1020–1022. [PubMed] [Google Scholar]
  9. Sclar D. A., Robison L. M., Skaer T. L. Pharmacy consultation and over-the-counter medication purchasing outcomes. Over-the-Counter Medication Intervention Project Team. J Clin Pharm Ther. 1996 Jun;21(3):177–184. doi: 10.1111/j.1365-2710.1996.tb00019.x. [DOI] [PubMed] [Google Scholar]
  10. Sihvo S., Ahonen R., Mikander H., Hemminki E. Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns. Fam Pract. 2000 Apr;17(2):145–149. doi: 10.1093/fampra/17.2.145. [DOI] [PubMed] [Google Scholar]
  11. Sobel J. D., Faro S., Force R. W., Foxman B., Ledger W. J., Nyirjesy P. R., Reed B. D., Summers P. R. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998 Feb;178(2):203–211. doi: 10.1016/s0002-9378(98)80001-x. [DOI] [PubMed] [Google Scholar]
  12. Sobel J. D., Vazquez J. A. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr;22(4):726–727. doi: 10.1093/clinids/22.4.726. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES